ClinicalTrials.gov
ClinicalTrials.gov Menu

Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02478177
Recruitment Status : Enrolling by invitation
First Posted : June 23, 2015
Last Update Posted : October 25, 2018
Sponsor:
Collaborators:
Janssen, LP
Genentech, Inc.
Daiichi Sankyo, Inc.
American Heart Association
Information provided by (Responsible Party):
Duke University

Brief Summary:
The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice.

Condition or disease
Stroke Cerebrovascular Stroke Intracerebral Hemorrhage

Detailed Description:

The ARAMIS Registry is a multicenter, cohort study of patients presenting with acute ischemic stroke (AIS) or intracerebral hemorrhage (ICH) while taking chronic anticoagulation therapy. The goals of ARAMIS are to (1) examine the prevalence of preadmission novel oral anticoagulants use among patients with AIS or ICH; (2) describe and characterize coagulation tests being used to assess the level of anticoagulation in these patients; (3) examine the utilization and safety profile of thrombolytic therapy in AIS patients taking new classes of anticoagulants; and (4) document treatment patterns of anticoagulation-related ICH and compare how care and outcomes vary by novel oral anticoagulants and warfarin. The acquisition of such findings will be of critical importance to help fill in gaps on guideline recommendations and provide insights into the management of AIS and ICH patients on treatment with new anticoagulants. This will allow physicians to feel more confident in anticoagulation therapy while improving the care and outcomes of patients on these agents who have stroke complications.

The ARAMIS builds upon the backbone of the nation's largest ongoing stroke registry, Get With The Guidelines-Stroke (GWTG-Stroke) by the American Heart Association/American Stroke Association (AHA/ASA). The GWTG-Stroke registry provides data on patient demographics, medical history, laboratory results, brain imaging, in-hospital treatment and outcomes. Using this existing resource, ARAMIS will create a new on-line supplemental data collection module and specifically collect information on medications prior to admission, diagnostic testing, treatment, factors associated with treatment decision making as well as clinical outcomes. A total of 10,000 consecutive patients 18 years or older, who experience an AIS (n=5,000) while taking a novel oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) or have an ICH (n=5,000) while taking warfarin or one of the novel oral anticoagulants within 7 days prior to the stroke onset will be enrolled in approximately 3-4 years. Beyond the index hospitalization, ARAMIS will enroll 2500 consecutive patients (1250 AIS and 1250 ICH) who survive and provide informed consent at discharge for the follow-up study. Trained personnel from the Duke Clinical Research Institute (DCRI) Call Center will conduct structured telephone interviews with these patients at 3 and 6 months following their index hospitalization. The follow-up interview will extend the baseline data collection at GWTG-Stroke and ARAMIS and include long-term medication, downstream care, and patient-reported outcomes, Obtaining such information will not only provide a longitudinal perspective on care and outcomes, but will also allow for innovative patient-centered outcomes and comparative effective research.


Study Type : Observational [Patient Registry]
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Management of Acute Stroke Patients on Treatment With Novel Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry
Study Start Date : September 2015
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Stroke
Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants



Primary Outcome Measures :
  1. Prevalence of novel oral anticoagulants among patients with either acute ischemic stroke or intracerebral hemorrhage [ Time Frame: Baseline ]
    Prevalence of novel oral anticoagulants will be abstracted from the medical record


Secondary Outcome Measures :
  1. Number of Symptomatic intracranial hemorrhage events in ischemic stroke patients treated with tissue plasminogen activator (tPA) [ Time Frame: Within 36 hours of tPA treatment ]
    Symptomatic intracranial hemorrhage within 36 hours from the time of tPA treatment will be abstracted from the medical record

  2. Percentage of Symptomatic intracranial hemorrhage events in ischemic stroke patients treated with tissue plasminogen activator (tPA) [ Time Frame: Within 36 hours of tPA treatment ]
    Symptomatic intracranial hemorrhage within 36 hours from the time of tPA treatment will be abstracted from the medical record

  3. Modified Rankin Scale [ Time Frame: Patients will be assessed at discharge as well as 3 months and 6 months after discharge ]
    Modified Rankin Scale at discharge will be abstracted from the medical record and Modified Rankin Scale at 3 months and 6 months will be obtained from follow-up telephone interview

  4. In-hospital mortality rate [ Time Frame: In-hospital mortality will be assessed for the duration of the patient's hospital stay (estimated 3-5 days) ]
    In-hospital mortality will be abstracted from the medical record

  5. tPA treatment rate [ Time Frame: tPA treatment will be assessed within 24 hours of admission ]
    tPA treatment among ischemic stroke patients will be abstracted from the medical record

  6. Number of intracerebral hemorrhage patients receiving anticoagulation reversal treatment [ Time Frame: During the acute phase, usually within 24 hours of admission ]
    This will be abstracted from the medical record

  7. Percentage of intracerebral hemorrhage patients receiving anticoagulation reversal treatment [ Time Frame: During the acute phase, usually within 24 hours of admission ]
    This will be abstracted from the medical record



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have had an acute ischemic stroke that has taken either dabigatran, rivaroxaban, apixaban, or edoxaban at least 7 days prior to admission OR patients who have had an intracerebral hemorrhage that has taken warfarin or one of the novel oral anticoagulants at least 7 days prior to admission.
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
  • Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the novel oral anticoagulants within 7 days prior to admission
  • ARAMIS follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate.

Exclusion Criteria:

  • Patients who are transferred from another hospital (unless directly transferred from another hospital emergency department (ED) within 24 hours) or discharged to other acute care facility will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02478177


Locations
United States, North Carolina
Duke Clinical Research Institute
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
Janssen, LP
Genentech, Inc.
Daiichi Sankyo, Inc.
American Heart Association
Investigators
Principal Investigator: Ying Xian, MD, PhD Duke UMC

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02478177     History of Changes
Other Study ID Numbers: Pro00059817
First Posted: June 23, 2015    Key Record Dates
Last Update Posted: October 25, 2018
Last Verified: October 2018

Keywords provided by Duke University:
Anticoagulant
Stroke
Ischemic Stroke
Intracerebral hemorrhage

Additional relevant MeSH terms:
Stroke
Hemorrhage
Cerebral Hemorrhage
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Intracranial Hemorrhages
Anticoagulants